SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 1999
COPLEY PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
0-20126 04-2514637
(Commission File Number) (IRS Employer Identification No.)
25 John Road
Canton, Massachusetts 02021
(Address of principal executive offices) (Zip Code)
(781) 821-6111
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events.
On February 8, 1999, Copley Pharmaceutical, Inc. announced that Charles T. Lay
joined its Board of Directors on February 3, 1999. With Mr. Lay's appointment,
Copley's Board of Directors comprises nine members, including a full complement
of three Independent Directors. Mr. Lay, the Company's second recent Independent
Board appointment, joins Jess G. Thoene, M.D., of the University of Michigan
School of Medicine, appointed in October 1998 and Robert P. Cook as Independent
Directors.
Until December 1998, Mr. Lay, 58, was President and CEO of Geneva
Pharmaceuticals, Inc., the U.S. generic drug subsidiary of Novartis AG. During
his tenure at Geneva, Mr. Lay directed the company's growth, resulting in its
becoming the second largest generic pharmaceutical company in the U.S. Revenue
during Mr. Lay's period of leadership tripled to $300 million and profits grew
ten-fold.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DATE COPLEY PHARMACEUTICAL, INC.
February 8, 1999 /s/ Daniel M. P. Caron
Vice President Finance, Chief Financial
Officer and Treasurer
(Principal Financial Officer)
